"Remaining on the speculative tack, drugmaker Shire firmed 0.4 per cent to 931p on renewed talk of a bid from Pfizer. Traders reckoned a bid from AstraZeneca, 0.7 per cent higher at £21.36, was more likely now that it had settled a patent dispute over top-selling ulcer treatment Nexium."
http://www.ft.com/cms/s/0/75c1c814-0b7f-11dd-9840-0000779fd2ac.html